Is RBM20 a Promising Target for HFpEF Therapy?
Wei Guo
Andrea R Sanchez Walk
10.25376/hra.7796618.v1
https://hra.figshare.com/articles/journal_contribution/Is_RBM20_a_Promising_Target_for_HFpEF_Therapy_/7796618
<div>
<div>
<div>
<p>Heart Failure (HF) is a major public health issue with an
estimated prevalence of over 37.7 million individuals worldwide
[1], and remains the leading cause of morbidity, mortality, and
hospitalization among adults and elderly [2,3]. In the USA, the
total medical costs for patients with HF are expected to rise
from US$20.9 billion in 2012 to $53.1 billion by 2030 [1]. About
half of the patients with heart failure display preserved ejection
fraction in contrast to the other half that present contractile
dysfunction and a dilated heart (HF with reduced ejection
fraction, HFrEF) [4,5]. Prototypical manifestations of heart
failure with preserved ejection fraction (HFpEF), previously
known as diastolic dysfunction, include increase in passive
stiffness, insufficient recoil, and decrease in full relaxation [6].
Anaggregation of severalcontributors such as hypertension,
metabolic syndrome, obesity and diabetes mellitus have
been associated with the development of HFpEF [6]. Despite
significant therapeutic improvements in the treatment of
virtually all cardiac disorders, HF is an exception, in that its
prevalence is rising, and its morbidity and mortality remain
unacceptably high [7,8]. Currently, no effective therapies are
available for HFpEF, at least with regard to major clinical events.
Therefore, novel insights into pathophysiology and molecular
mechanisms of HFpEF progression are required to develop novel
therapeutic approaches.</p>
<div>
<div>
<div>
<p><br></p></div></div><div><div>
</div>
</div>
</div>
</div>
</div>
</div>
2019-03-03 18:12:05
Titin isoform switching
Alternative splicing
HFpEF
RBM20
Biomarkers
Cardiology (incl. Cardiovascular Diseases)
Molecular Targets